glp-1 weight loss drugs competitive analysis Chart: Most Americans Prefer Exercise Over GLP-1 Agonists Market Report 2025-2033,

Some patients experience dramatic weight loss, while others see more modest changes

Clinical Evidence Review (2025 Update) The clinical landscape of GHK-Cu has matured since the early 2000s, with several peer-reviewed human studies now confirming moderate but measurable benefits

Pola P, Savi L, Grilli M, Flore R, Serricchio M

Comparison conditions were as follows: month 0, accelerated 6 months and extended 12 months of testing

The solvent affects the peptides solubility and stability, so its important to follow the guidelines provided for each peptide

The catalog is smaller than a few rivals here, but that reads as deliberate curation rather than a gap